My Authors
Read all threads
#AlembicPharma Good potential. 2500 Cr Capex till 2021 ongoing. Entered in high margin injectable business. Capex on Oncology injectable facility ongoing. Injectables have more stringent FDA requirements than oral dosages. Hence less competitive.
RnD expenditure is an important parameter for identifying the future potential for a pharma company. 650 Cr spent in 2020. This should reflect in earnings in the coming years. The stock price might discount this before 2021.
New Drug Discovery unit:
Rhizen pharma situated in Switzerland seems to have a strong pipeline in Oncology and immunology. This is the NCE space where very few Indian companies are investing.…
Latest investor presentation shows US sales rising

D: Invested.…
Missing some Tweet in this thread? You can try to force a refresh.

Keep Current with Prasad Wakchaure 🇸🇪 🇮🇳

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!